NASDAQ$TELA
TELA Bio Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2020.
TELA Bio's revenue for Q1 2020 was $3.7 million, a 13% increase compared to the prior year period. However, the company experienced a negative impact on revenues in the second half of March due to the deferral of elective surgical procedures related to the COVID-19 pandemic. The company is confident in its strong foundation of innovative products and dedicated team.
- Revenue increased by 13% to $3.7 million compared to the prior year period.
- Gross profit was $2.2 million, representing 59% of revenue, compared to 54% in the same period in 2019.
- Operating expenses increased to $8.7 million due to the expansion of the company’s commercial organization and increased costs associated with operating as a public company.
- Net loss was $7.2 million, compared to a net loss of $6.0 million in the same period in 2019.
Headline financials
Revenue & EPS history
TELA Bio · Revenue · Quarterly
$3.73M
Forward guidance
The Company expects revenue to decline in the second quarter of 2020 as compared to the most recent completed quarter and same quarter in 2019.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2020
-2.5%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+20.2%
Q1 2024
Best reaction
-37.2%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.7% | -9.3% | — | |
| Q1 2026 | -5.3% | -18.6% | -15.7% | |
| Q3 2025 | -9.3% | -2.7% | +3.6% | |
| Q1 2025 | +7.2% | -0.1% | +90.7% | |
| Q4 2024 | -37.2% | -44.9% | -59.1% | |
| Q3 2024 | +2.0% | +3.0% | -1.7% | |
| Q2 2024 | -23.9% | -23.4% | -35.0% | |
| Q1 2024 | +20.2% | +21.2% | +16.7% | |
| Q4 2023 | +4.0% | +0.9% | -13.8% | |
| Q3 2023 | -20.3% | -21.7% | -4.5% | |
| Q2 2023 | -4.8% | -1.2% | -2.8% | |
| Q1 2023 | -3.6% | -4.8% | +11.2% | |
| Q4 2022 | -5.5% | -3.7% | -11.3% | |
| Q3 2022 | +13.8% | +11.2% | +44.7% | |
| Q2 2022 | -6.5% | +5.5% | +0.9% | |
| Q1 2022 | -5.7% | -7.0% | -31.4% | |
| Q4 2021 | -4.8% | -4.8% | -20.4% | |
| Q3 2021 | -3.8% | -3.7% | -1.7% | |
| Q2 2021 | +5.0% | +4.4% | -8.3% | |
| Q1 2021 | +3.2% | +11.5% | +5.9% | |
| Q4 2020 | -6.6% | +0.9% | -1.8% | |
| Q3 2020 | -3.5% | -0.8% | -3.6% | |
| Q2 2020 | +5.4% | +4.1% | +20.7% | |
| Q1 2020 | -2.4% | -3.6% | +38.6% | |
| Q4 2019 | +0.6% | -0.4% | +34.0% | |
| Q3 2019 | +13.9% | +8.8% | +32.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro